Etoposide with/without G-CSF with busulfan and cyclophosphamide as conditioning for bone marrow transplantation
| Autor: | Yoshinobu Kanda, Hideki Akiyama, Shu Tanikawa, Hisashi Sakamaki, Tsuneo Sasaki, Shigeru Takamoto, Yasusuke Onozawa, Bmt Team |
|---|---|
| Rok vydání: | 1996 |
| Předmět: |
medicine.medical_specialty
Chemotherapy Hepatic veno-occlusive disease Cyclophosphamide business.industry medicine.medical_treatment Hematology medicine.disease Gastroenterology Granulocyte colony-stimulating factor Surgery medicine.anatomical_structure Internal medicine Mucositis Medicine Bone marrow business Busulfan Etoposide medicine.drug |
| Zdroj: | American Journal of Hematology. 51:265-268 |
| ISSN: | 1096-8652 0361-8609 |
| DOI: | 10.1002/(sici)1096-8652(199604)51:4<265::aid-ajh3>3.0.co;2-u |
| Popis: | To increase the efficacy of bone marrow transplantation (BMT), we have tried to add etoposide (VP-16) to busulfan/cyclophosphamide (BU/CY). Twelve patients received 16 mg/kg of BU and 120 mg/kg of CY with 15-30 mg/kg of VP-16. Another two patients received 5 micrograms/kg of G-CSF with 30 mg/kg of VP-16. Patients tolerated escalating doses of VP-16 without any significant hepatotoxicity. Their maximal level of bilirubin was 37.6 micromol/L (2.2 mg/dl), and there was no significant skin toxicity or mucositis. By contrast, two patients who received G-CSF with 30 mg/kg of VP-16 developed hyperbilirubinemia and veno-occlusive disease, which terminated this phase I study. VP-16 can be safely combined with BU/CY < or = 30 mg/kg in three divided doses, and its effect on survival should be evaluated. G-CSF added to this regimen, however, should be used with great caution. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text